Clinical trial NCT05458752: Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients
Official title: Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients : a Prognostic Observational Retrospective Monocentre Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pneumocystis Jirovecii Infection
Keywords: pneumocystis jirovecii pneumonia
HIV-free patients
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2022-07-14
Enrollment: 133
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients without HIV-infection hospitalised in Nancy hospital between 2004 and 2021 for Pneumocystis jirovecii pneumonia

Brief summary: Pneumocystis jirovecii pneumonia (PjP) is a rare infectiouse disease with a high level of mortality. PjP is a classical opportunistic infection which concern HIV infected and immunocompromised patients. During the past decade, several therapeutic's progresses have been done in oncology, immunology and hematology. As a consequence, patients benefited of greater treatment efficacy but are exposed to a higher risk of opportunistic infections as PjP. The investigators hypothesis is that PjP incidence increase and its form is depending of underlying immune conditions. The investigators aim to describe its incidence, the PjP forms depending on comorbidities and to identifiy pronostics factors.


Eligibility criteria: Inclusion Criteria:

* Underlying immune condition at risk of Pneumocystis jirovecii pneumonia excluding HIV infection
* Clinical, biological and radiological presentation which evoke Pneumocystis jirovecii pneumonia
* Microbiological confirmation by respiratory specimen analyses ( specific coloration and/or IFI and/or PRC)

Exclusion Criteria:

* No microbiological confirmation by respiratory specimen analyses
* Proved HIV infection
* Patient denied to particpate

Primary outcomes:
measure: Incidence of Pneumocystis jirovecii pneumonia in HIV-free patients
timeFrame: Between the first january 2004 and the 31th december 2021
Secondary outcomes:
measure: To describe the age of giv free patients with Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the body mass index of HIV free patients with Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the Charlson comorbidity index of HIV free patients with Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the comoribidites of HIV-free patients with Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the previous medications used by HIV free patients with Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe clinical features of Pneumocystis jirovecci pneumonia in HIV-free patients
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the date of the first symptoms of Pneumocystis jirovecci pneumonia in HIV-free patients
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the pO2 level of HIV free patients with Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the PCR level of HIV free patients with Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the WBC level of HIV free patients with Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the creatinine level of HIV free patients with Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the LDH level of HIV free patients with Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the albumin level of HIV free patients with Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the immunoglobulin level of HIV free patients with Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the lymphocytes level of HIV free patients with Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the PCR pneumocystis level of HIV free patients with Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the immunofluorescence value of HIV free patients with Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the specific coloration value of HIV free patients with Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the use of nasal canula in HIV free patient with a Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the use of high flow oxygenation in HIV free patient with a Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the use of mechanical ventilation in HIV free patient with a Pneumocystis jirovecci pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the duration of hospitalisation of HIV free patients with Pneumocystis carinii pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the use of cotrimoxazole for HIV free patients with Pneumocystis carinii pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the use of atovaquone for HIV free patients with Pneumocystis carinii pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the use of pentamidine for HIV free patients with Pneumocystis carinii pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
measure: To describe the use of steroïd for HIV free patients with Pneumocystis carinii pneumonia
timeFrame: Between the first january 2004 and the 31th december 2021
Other outcomes:
Locations:
city: Vandoeuvre Les Nancy
country: France
facility: Université de Lorraine, CHRU Nancy and APEMAC
state: Lorraine
Study officials:
References: